Alzheimer’s disease is a devastating neurodegenerative disorder, afflicting 1 in 3 dying seniors and costing $236 billion annually in the United States alone. Its prevalence is increasing rapidly in an aging population, and currently there is no cure. Recent genetic studies provide new hope for therapeutic avenues, but translating genetic results into therapeutics has been remarkably difficult, due primarily to the fact that most genetic mutations do not alter protein function directly, but instead affect the expression of nearby genes in subtle ways. Here, we seek to overcome this limitation by directly profiling the gene-regulatory differences in Alzheimer’s patients, to understand the cell types, regulatory regions, target genes and upstream regulators whose function is affected in disease. We profile epigenomic differences in Alzheimer’s disease across 600 individuals, we dissect the cell-type-specific action of these differences in neurons, astrocytes and microglial cells, and we map the detailed circuitry of brain regulatory regions across Alzheimer’s patients and controls. The resulting datasets will be released broadly to the scientific community, and also form the foundation for computational and experimental work by the Cure Alzheimer’s Fund’s CIRCUITS consortium, in order to translate the resulting datasets into mechanistic insights and new therapeutic avenues for Alzheimer’s.
CIRCUITS: Production Center for Reference and Variation Gene-Regulatory Maps
Funding to date:
© 2005-2017 Cure Alzheimer's Fund. All rights reserved.